Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 15/20 | 0.57 |
| ▸ | BRAF | P15056 | 14/20 | 0.57 |
| ▸ | KDR | P35968 | 6/20 | 0.57 |
| ▸ | FLT1 | P17948 | 4/20 | 0.57 |
| ▸ | RAF1 | P04049 | 2/20 | 0.57 |
| ▸ | LCK | P06239 | 2/20 | 0.57 |
| ▸ | RET | P07949 | 2/20 | 0.57 |
| ▸ | MAP3K20 | Q9NYL2 | 2/20 | 0.57 |
| ▸ | RIPK3 | Q9Y572 | 2/20 | 0.57 |
| ▸ | CIT | O14578 | 1/20 | 0.57 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.57 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.57 |
| ▸ | STK10 | O94804 | 1/20 | 0.57 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.57 |
| ▸ | ABL1 | P00519 | 1/20 | 0.57 |
| ▸ | EGFR | P00533 | 1/20 | 0.57 |
| ▸ | FYN | P06241 | 1/20 | 0.57 |
| ▸ | CSF1R | P07333 | 1/20 | 0.57 |
| ▸ | YES1 | P07947 | 1/20 | 0.57 |
| ▸ | LYN | P07948 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3151777 | 0.91 | KDR (0.71) | KITBRAFKDRFLT1RAF1 | |
| SCHEMBL6387675 | 0.84 | KDR (0.64) | KITBRAFKDRFLT1RAF1 | |
| SCHEMBL5626946 | 0.82 | KIT (0.78) | KITBRAFKDRFLT1RAF1 | |
| SCHEMBL5626160 | 0.82 | KDR (0.42) | KITBRAFKDRFLT1RAF1 | |
| SCHEMBL446984 | 0.81 | KDR (0.42) | KITBRAFKDRFLT1RAF1 | |
| SCHEMBL4984362 | 0.80 | KDR (0.68) | KITBRAFKDRFLT1RAF1 | |
| SCHEMBL4974477 | 0.79 | KDR (0.69) | KITBRAFKDRFLT1RAF1 | |
| SCHEMBL14348641 | 0.78 | KIT (0.61) | KITBRAFKDRFLT1RAF1 | |
| SCHEMBL3154513 | 0.78 | KDR (0.55) | KITBRAFKDRFLT1RAF1 | |
| SCHEMBL5009499 | 0.78 | KDR (0.68) | KITBRAFKDRFLT1RAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040087568-A1 | Substituted anthranilic amide derivatives and methods of use | AMGEN INC. | 2004-05-06 | — | — | US | claimed |
| US-7307088-B2 | Substituted anthranilic amide derivatives and methods of use | AMGEN INC. (US) | 2007-12-11 | — | — | US | disclosed |
| US-7307088-B2 | Substituted anthranilic amide derivatives and methods of use | AMGEN INC. (US) | 2007-12-11 | — | — | US | disclosed |
| US-7307088-B2 | Substituted anthranilic amide derivatives and methods of use | AMGEN INC. (US) | 2007-12-11 | — | — | US | disclosed |
| EP-1519921-A2 | SUBSTITUTED ANTHRANILIC AMIDE DERIVATIVES AND METHODS OF USE | Amgen Inc. (US) | 2005-04-06 | — | — | EP | disclosed |
| US-20040087568-A1 | Substituted anthranilic amide derivatives and methods of use | AMGEN INC. | 2004-05-06 | — | — | US | disclosed |
| WO-2004005279-A2 | SUBSTITUTED ANTHRANILIC AMIDE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087568-A1 | Substituted anthranilic amide derivatives and methods of use | AADAC, ASPH, EGLN3 | KIT 1087/4885BRAF 469/4885KDR 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.